fda warning letter compounding semaglutide news Out of Shortage, Into Controversy: The Fight Over GLP-1 FDA Issues Warning Letters to

My one complaint is that the pricing page is the only place medication pricing appears

This multi-receptor activation enables: GLP-1R activation enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic signaling GIPR activation (highest potency: EC50 0.0643 nM) promotes insulin secretion and modulates lipid metabolism GCGR activation (EC50 5.79 nM) increases energy expenditure and promotes hepatic fat oxidation Combined receptor engagement produces dose-dependent reductions in body weight and improvements in glycemic control Research demonstrates that GLP3s balanced activation across three receptors produces superior metabolic effects compared to single or dual agonists, with phase 2 trials showing up to 24.2% weight reduction in 48 weeks[2]

orange = dual GLP-1/GIP agonists and cardiovascular outcomes

Boekhoorn 2007)